370 related articles for article (PubMed ID: 24055775)
41. Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b as bone resorption marker in irradiated bone metastases.
Mose S; Menzel C; Kurth AA; Obert K; Ramm U; Eberlein K; Boettcher HD; Pichlmeier U
Anticancer Res; 2005; 25(6C):4639-45. PubMed ID: 16334155
[TBL] [Abstract][Full Text] [Related]
42. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.
Halleen JM; Ylipahkala H; Alatalo SL; Janckila AJ; Heikkinen JE; Suominen H; Cheng S; Väänänen HK
Calcif Tissue Int; 2002 Jul; 71(1):20-5. PubMed ID: 12073156
[TBL] [Abstract][Full Text] [Related]
43. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM
Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213
[TBL] [Abstract][Full Text] [Related]
44. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
[TBL] [Abstract][Full Text] [Related]
45. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer.
Horiguchi T; Tachikawa S; Kondo R; Hirose M; Teruya S; Ishibashi A; Banno K
Jpn J Clin Oncol; 2000 Apr; 30(4):174-9. PubMed ID: 10830985
[TBL] [Abstract][Full Text] [Related]
46. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.
Hannon RA; Clowes JA; Eagleton AC; Al Hadari A; Eastell R; Blumsohn A
Bone; 2004 Jan; 34(1):187-94. PubMed ID: 14751577
[TBL] [Abstract][Full Text] [Related]
47. Characteristics of bone turnover markers in rapidly destructive coxopathy.
Abe H; Sakai T; Ogawa T; Takao M; Nishii T; Nakamura N; Sugano N
J Bone Miner Metab; 2017 Jul; 35(4):412-418. PubMed ID: 27550182
[TBL] [Abstract][Full Text] [Related]
48. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
49. Potential role of tartrate-resistant acid phosphatase 5b (TRACP 5b) as a surrogate marker of late loosening in patients with total hip arthroplasty: a cohort study.
Savarino L; Avnet S; Greco M; Giunti A; Baldini N
J Orthop Res; 2010 Jul; 28(7):887-92. PubMed ID: 20063383
[TBL] [Abstract][Full Text] [Related]
50. [Studies of type I collagen related substances as bone metastatic markers of prostate carcinoma with special regard to serum carboxyterminal propeptide of type. I. Procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and Urinary deoxypyridinoline levels].
Imai T; Honda M; Maeda S; Hosoya Y; Arai T; Sumi S; Umeda H; Yano M; Koga F; Arai K; Yoshida K
Nihon Hinyokika Gakkai Zasshi; 1998 Apr; 89(4):484-91. PubMed ID: 9597867
[TBL] [Abstract][Full Text] [Related]
51. Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen.
Kataoka A; Yuasa T; Kageyama S; Tsuchiya N; Habuchi T; Iwaki H; Narita M; Okada Y; Yoshiki T
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):480-4. PubMed ID: 16909972
[TBL] [Abstract][Full Text] [Related]
52. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients.
Fonseca R; Trendle MC; Leong T; Kyle RA; Oken MM; Kay NE; Van Ness B; Greipp PR
Br J Haematol; 2000 Apr; 109(1):24-9. PubMed ID: 10848778
[TBL] [Abstract][Full Text] [Related]
53. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
54. Tartrate-resistant acid phosphatase isoform 5a as an inflammation marker in end-stage renal disease.
Janckila AJ; Lederer ED; Price BA; Yam LT
Clin Nephrol; 2009 Apr; 71(4):387-96. PubMed ID: 19356371
[TBL] [Abstract][Full Text] [Related]
55. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years.
Rauchenzauner M; Schmid A; Heinz-Erian P; Kapelari K; Falkensammer G; Griesmacher A; Finkenstedt G; Högler W
J Clin Endocrinol Metab; 2007 Feb; 92(2):443-9. PubMed ID: 17105843
[TBL] [Abstract][Full Text] [Related]
56. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity.
Janckila AJ; Takahashi K; Sun SZ; Yam LT
Clin Chem; 2001 Jan; 47(1):74-80. PubMed ID: 11148180
[TBL] [Abstract][Full Text] [Related]
57. Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase.
Fischer DC; Mischek A; Wolf S; Rahn A; Salweski B; Kundt G; Haffner D
Ann Clin Biochem; 2012 Nov; 49(Pt 6):546-53. PubMed ID: 22984195
[TBL] [Abstract][Full Text] [Related]
58. Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.
Okuno S; Ishimura E; Tsuboniwa N; Norimine K; Yamakawa K; Yamakawa T; Shoji S; Mori K; Nishizawa Y; Inaba M
Osteoporos Int; 2013 Feb; 24(2):605-12. PubMed ID: 22581293
[TBL] [Abstract][Full Text] [Related]
59. Development of a kinetic assay for band 5b tartrate-resistant acid phosphatase activity in serum.
Nakanishi M; Yoh K; Miura T; Ohasi T; Rai SK; Uchida K
Clin Chem; 2000 Apr; 46(4):469-73. PubMed ID: 10759470
[TBL] [Abstract][Full Text] [Related]
60. The efficacy of a serum carboxyterminal pyridinoline cross-linked telopeptide of type I collagen as a quantitative screening marker for bone metastases in patients with urological malignancies.
Okamura T; Akita H; Tatsura H; Kawai N; Nagata D; Azemoto M; Iwase Y; Kohri K
Cancer Detect Prev; 2003; 27(1):14-8. PubMed ID: 12600412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
